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INTRODUCTION
Completion of treatment for latent tuberculosis infection is emerging as a major
component of the tuberculosis (TB) control program in the United States. Health Care
Workers (HCWs) are a particularly important target population for this intervention
because—if they themselves develop TB disease—they place at risk the many patients
regularly encountered in their work.
Completion rates for treatment of latent TB infection are modest across treatment
programs in general. Initiation and successful completion of therapy for latent TB
infection among HCWs constitutes a particularly important goal—and a major challenge.
Appropriate strategies are needed that can (1) identify the reasons for poor treatment
initiation rates, (2) clarify the basis for poor adherence among those initiating treatment,
and (3) promote high rates of initiation and completion of treatment.
At the Charles P. Felton National Tuberculosis Center at Harlem Hospital, we developed a
program that was able to identify the underlying barriers and then dramatically improve
rates of initiation and completion of treatment of latent TB infection. Through this
process we learned a great deal that can be generalized to other health care institutions
across the country. The purpose of this guide is, first, to summarize the highlights of our
program, and then describe the steps that other institutions can follow in designing and
implementing a program of their own.
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BACKGROUND
At Harlem Hospital we observed that many HCWs referred to the Chest Clinic from the
Employee Health Service (EHS) because of a positive tuberculin skin test (TST) either did
not keep their appointments, or did not return after their initial visit. In addition, only a
small proportion of those HCWs who initiated treatment for latent TB infection returned
to the Clinic for their monthly visits and continued to take their medication.
We documented the rates of initiation and completion of treatment for latent TB
infection over a one-year period among HCWs at Harlem Hospital by reviewing the charts
and pharmacy records of all HCWs who were found to be TST positive during an annual
or pre-employment physical. This constituted our pre-intervention baseline data. It
showed that, prior to our new program, only 55% of HCWs at Harlem Hospital who were
eligible for treatment of latent TB infection actually began their treatment. Of those who
began and were scheduled to finish in 6 months, only 11% completed therapy.
Barriers to initiation and completion of treatment were identified through interviews
with hospital HCWs, chest clinic staff, and staff at EHS. Some of the barriers to initiation
included lack of knowledge about TB and fear of medication side effects. Barriers to
completing treatment included long wait times, inflexible appointment schedules,
lengthy assessments by multiple providers, and lack of an appointment reminder system.
Based on these findings, we developed a series of potential solutions to address these
barriers. We initiated a multifaceted program the following year, including educational,
structural, and supportive components, e.g., provision of specific educational materials,
expedited medical assessment, and an active reminder system. 
In the first full year of the implementation of the new “Fast Track” program, 72% of
eligible employees initiated therapy. Of those eligible for completion, 81% actually did so. 
This guide describes the procedures we followed and delineates methods that may be
useful for other institutions to develop a similar program.
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BASELINE DOCUMENTATION AND 
PREPARATORY STEPS
1. Discuss the program to be developed with decision-makers in the relevant departments.
Obtain their input on how to define the scope of the problem and collect data.
2. Identify the scope of the current problem in the facility. Before designing and
implementing a program to improve initiation and completion of latent TB infection
treatment, it is essential to determine current treatment completion rates. If available,
data from Employee Health Service (EHS) on current rates of initiation and completion
of treatment for latent TB infection should be collected for the preceding year. This
can be used to set appropriate objectives and monitor the program.
 EHS can assist in retrieving the names of all employees who were TST positive
during their annual assessment the previous year. The data to be collected should
include: number of HCWs skin tested; number who returned for reading; number
who were eligible for latent TB infection treatment; number who initiated
treatment for latent TB infection; and number who completed treatment. The
rates of initiation and completion of treatment for latent TB infection should be
calculated. Treatment completion rates should be broken down by informative
categories, e.g. age, job category, gender (see sample characteristics in Appendix A).
 A review of the pharmacy list of all HCWs who picked up medication each month,
if available, will indicate whether HCWs retrieved their medication supply at the
specified intervals.  This list can be obtained from the main pharmacy in your
institution; however, it might be difficult to obtain due to confidentiality concerns
and your agency’s policy.
3. Identify barriers that stand in the way of initiation and completion of treatment. This
can be done through interviews or focus group discussions with employees, clinic
staff, and the staff of the EHS.  The primary principle to keep in mind is the necessity
of seeking information from a diversity of providers on the one hand, and of HCWs
(clients) on the other.
4. Take the data back to decision-makers. All of the relevant departments, such as EHS
and Human Resources, must be on-board and involved in structuring the solutions.
You will need their buy-in for the new program to be successful. 
5. Give one person—the Program Coordinator—the responsibility to serve as educator,
navigator, and support system for the HCWs. Once the program is established, this
may only be a part-time task. The role of the “Program Coordinator” is described
further on pages 8-9. A designated person must play this key role in order for the
program to be successful.
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PROGRAM DEVELOPMENT:
A. Potential Barriers
The following are some of the barriers that were identified through interviewing HCWs
at Harlem Hospital, staff at EHS, and staff at the chest clinic.  Barriers may differ at your
facility; this should be taken into account when developing this component of your
program.
Scheduling and Structural Issues
DELAYS IN HCWS GETTING SERVICES IN EHS, CHEST CLINIC, X-RAY DEPARTMENT,
LABORATORY, AND PHARMACY:
 Lengthy waiting times
 Lengthy assessments by multiple providers (e.g. nurse, then MD, back to nurse)
 Lack of rapid access to medications
SYSTEMS MAY BE WEAK OR LACKING FOR:
 Tracking appointments and reminding clients ahead of time
 Reinforcing the importance of initiation and completion of treatment for latent TB
infection
 In addition, work schedules may make it difficult for HCWs to keep appointments
during working hours.
Information and Attitudinal Issues
 Fear of medication side effects
 Belief that prior BCG vaccination protects against development of TB disease
 Belief that prior BCG vaccination is responsible for the positive TST
 Perception of not being at risk for TB, and thus not needing treatment
 Lack of knowledge about TB, especially the context and importance of treating latent
TB infection
 Cultural beliefs that TB infection and TB disease can be treated with alternative
modalities, e.g., herbs
 Confidentiality concerns, i.e., fear that others may find out that they are being treated
for latent TB infection
 Health care providers are unclear about indications for treatment of latent TB
infection
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PROGRAM DEVELOPMENT:
B. Barriers and Potential Solutions
Scheduling and Structural Issues
LONG WAIT IN EHS, CLINIC, X-RAY DEPARTMENT, LABORATORY, OR PHARMACY
1. Develop pre-packaged evaluation kits for EHS to give to HCWs. These kits contain
educational materials (see Appendices B, C, D, and E), intake form (Appendix F), X-ray
and lab requisition slips. Requisition slips are distinctively colored and stamped
PRIORITY. HCWs go to X-ray and lab before going to the chest clinic.
2. In the chest clinic, establish separate medical records for employees (duplicate record
is made using carbonless copy paper; a copy of which should be sent to EHS).  These
medical records can be of a different color from those of other clinic patients and
they can be kept in a different location, possibly with the Program Coordinator.  This
ensures easy access to the medical records.
3. Facilitate rapid evaluation by prioritizing clinic visits and expediting laboratory tests
and radiologic assessments. The Program Coordinator should then be informed by
EHS whenever an employee is referred to the clinic. When an employee comes to the
clinic, the Program Coordinator should ensure that the employee gets registered and
sees the physician and nurse immediately. This is especially important due to the time
constraints of HCWs. 
4. Provide medications directly to the HCW on the day of the scheduled visit. The
Program Coordinator should pick up the medication from the pharmacy before the
employee comes to the clinic—in order to speed up the process. 
5. Use a self-assessment tool (see Appendix G) to be completed by the employee at each
monthly visit. The Coordinator should review the questionnaire. Employees with no
side effects or complaints or morbid conditions then pick up their medication
immediately from the Coordinator. 
FORGETTING CLINIC APPOINTMENTS, OR UNABLE TO KEEP AN APPOINTMENT
1. Develop a reminder system to inform patients of an upcoming appointment.
Employees should be called the day before their scheduled appointment to be
reminded of the time and place.
2. Reschedule missed appointments promptly.  If an appointment is missed, the Program
Coordinator should call the employee and schedule another as soon as possible.
3. The Program Coordinator must keep a record of all appointments missed and phone
calls made, using the activity and visit outcome forms (see Appendices H and I).
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Information and Attitudinal Issues
FEAR OF SIDE EFFECTS FROM MEDICATION
 Provide educational materials that describe potential side effects, their likelihood,
how to monitor for side effects, and how to manage them if they occur (see
brochure, Appendix D and fact sheet, Appendix E) 
 The Program Coordinator should be available to the HCW to answer all related
questions and concerns.
 HCWs should be encouraged to call the Program Coordinator at any time if they have
additional questions or concerns.
MISCONCEPTIONS ABOUT BCG VACCINE
 Provide educational materials about BCG, information on its effectiveness, its impact
on TST interpretation, etc. (see Appendix C). A HCW from the same or similar
background, who has completed treatment for latent TB infection, can be especially
useful.
 Commonly asked questions and answers:
Question: Could the BCG vaccine have caused my TB test to be positive?
Answer: It could, but the positive skin test is more likely to indicate latent TB
infection. This is because BCG is usually given in countries with high rates of TB, 
where risk of infection is substantial.
Question: Will the BCG vaccine prevent me from getting TB infection or TB disease?
Answer: The BCG vaccine does not prevent TB infection or TB disease in adults.
LACK OF KNOWLEDGE ABOUT TB INFECTION, PERCEPTION OF NOT BEING AT RISK,
AND SPECIFIC CULTURAL BELIEFS
 One-on-one education of HCWs: start by administering the knowledge and attitudes
questionnaires (Appendix J) and listening to their beliefs; build on what they already
know
 Provide information about the importance of completing treatment for latent TB
infection in language the client understands
 Do not discourage alternative treatments if they will do no harm and the client
agrees to take treatment for latent TB infection at the same time
 Encourage HCWs to call the Program Coordinator if they have any questions or
concerns
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CONFIDENTIALITY CONCERNS
 HCWs’ absence from daily routine is rarely noticed because systems effectively provide
rapid medical evaluation, self-assessment of side effects, and resupply of medications
 If medications are delivered to HCW outside the clinic, this is done inconspicuously 
 HCWs’ charts are maintained by the Program Coordinator; only direct providers of care
are given access
 Final disposition of treatment for latent TB infection becomes a part of the HCW’s
confidential medical record at EHS 
HEALTH CARE PROVIDERS ARE UNCLEAR ABOUT INDICATIONS FOR TREATMENT OF
LATENT TB INFECTION
 Educate and train providers in the EHS (physicians, physician assistants, and nurses)
 Educate and train treating physicians in your clinic so that they can reinforce the
importance of treatment of latent TB infection in appropriate candidates. This
training can use didactic materials, as well as develop communication skills through
role-playing.
 Implement in-house training for other providers, e.g., nurses, social workers.
Training materials can be obtained from the National TB Centers, the Centers for Disease
Control and Prevention (CDC), and your local or state health departments. The Program
Coordinator should identify appropriate training materials and facilitate access to them
(see Appendix K).
PROGRAM DEVELOPMENT:
C. Getting Started
Key Program Components
1. Identify a Program Coordinator, e.g., health educator, social worker, caseworker, or
nurse, to spearhead the program. This person will have the role described below and
should be selected based on their TB knowledge, good communication skills, and
resourcefulness.
2. Develop systems to expedite patient registration and medication pick up.  This can be
accomplished through training of clerical staff and nursing staff to the specific needs
of HCW clients.
3. Develop a reminder system for appointments and a follow-up system for missed
appointments.  The Program Coordinator should maintain records of HCW’s
appointments, status of completion of appointment, record of reminder calls, etc. 
(see Appendices H and I).
4. Develop a self-assessment tool to monitor side effects and eliminate unnecessary
delays due to consultations with providers (see Appendix G).
5. Develop special medical records for HCWs that are kept at the Clinic to expedite
assessments. The HCW’s medical records should include: initial registration form, 
monthly self-assessment forms, TB knowledge and attitude questionnaire, laboratory
results, and referral with TB skin test result from EHS.
6. Give priority for HCWs to see provider. If needed, the Program Coordinator should
serve as a liaison and facilitator to expedite assessment.  
7. Develop a stream-lined way of resupplying medications on a monthly basis with no
delay for the HCW, who has to take time out of his/her busy workday.  The Program
Coordinator should secure the prescription, obtain medication from the pharmacy,
and deliver it to the HCW.
8. Provide appropriate educational materials targeted to HCWs to provide information
on latent TB infection therapy, BCG, and other relevant issues.  Such materials can be
obtained from your local or state health department or the Centers for Disease
Control and Prevention.  The Program Coordinator should ensure that appropriate
educational materials are available (see Appendices B, C, D, E, and K).
9. Develop a marketing plan for disseminating information about the program.  This
plan may include developing a brochure (see Appendix B), promoting the program at
in-service training, and communicating information through departmental
conferences.
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PROGRAM DEVELOPMENT:
D. Role of the Program Coordinator
The key component in overcoming barriers is the identification of a person to coordinate
this process. This person may be a health educator, a nurse, or another staff member.
Once the program is established, this is usually only a part-time task.
WHAT THE HCW/CLIENT DOES WHAT THE PROGRAM COORDINATOR DOES
Goes to EHS for the required annual or
pre-employment physical exam, including
TST
Reports to the Clinic if TST is positive; get
chest x-ray and medical assessment to see
if treatment for latent TB infection is
recommended
Becomes informed about TB infection
and disease, and the importance of
completing treatment for latent TB
infection
Comes to the Clinic or another
convenient location for monthly self-
assessment visits and resupply of
medications
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Establishes a close, collaborative
relationship with EHS team; serve as liaison
to the EHS
Establishes a close, collaborative
relationship with the clinic team; serve as
liaison to the clinic
1. If employee is not a candidate for
treatment of latent TB infection:
educates employee about TB, infection
control, signs and symptoms of TB
disease, and seeking medical assistance
if these appear
2. If treatment of latent TB infection is
recommended for employee:
 Educates employee about TB,
treatment for latent TB infection,
side effects, and importance of
completion of treatment
 Gives monthly reminder before next 
appointment
 Has pre-filled prescriptions ready
 Gives employee self-assessment form
 Gives 1-month supply of medications
if no complaints of side effects
 Arranges immediate consultation
with physician or nurse, if needed
 Follows-up missed appointments 
promptly
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EVALUATION OF PROGRAM OUTCOMES
Development of an evaluation plan is critical before initiating the program. Assessment
should take place at predetermined intervals to identify any need for modifications in
the program. Outcomes of potential interest include the following:
 Proportion of eligible HCWs who initiate treatment for latent TB infection
 Proportion of scheduled visits completed
 On-time treatment completion rate
 HCW satisfaction with the program (see Appendix L)
The following shows an example of before and after evaluation:
EXAMPLE: HOSPITAL X
BEFORE INTERVENTION # % AFTER INTERVENTION # %
# employees tested 700 # employees tested 700
# returned for reading 680 # returned for reading 680
% returned for reading 680/700 97% % returned for reading 680/700 97%
# TST positive 88 # TST positive 88
% TST positive 88/680 13% % TST positive 88/680 13%
# eligible for  Tx 70 # eligible for Tx 72
% eligible for Tx 70/88 80% % eligible for Tx 72/88 82%
# who initiate Tx 35 # who initiate Tx 61
% who initiate Tx 35/70 50% % who initiate Tx 61/72 85% 
# who complete Tx 4 # who complete Tx 52
% who complete Tx 4/35 11% % who complete Tx 52/61 85%
APPENDIX A: Characteristics of Employees Starting  
Latent TB Infection Treatment at Hospital X
NUMBER COMPLETION
CHARACTERISTICS OF EMPLOYEES NUMBER PERCENT COMPLETING RATE
Gender
Male 48 63% 6%
Female 28 37% 14%
Age Range 19-69
Median Age 34
EMPLOYEE TYPE
Physician/PA 29 38% 1 3%
Nurses 3 4% 1 33%
Volunteer/Students 13 17% 1 8%
Clerical/Case Manager 10 13% 2 20%
Food Services/Housekeeping 8 11% 1 12%
Other 13 17% 2 16%
Total 76 100% 8
APPENDIX B: BROCHURE – Fast-Track TB Special Program
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APPENDIX D: Brochure – Therapy to Prevent Tuberculosis
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APPENDIX E: Brochure —Facts about INH
New York City Department of Health
BUREAU OF TUBERCULOSIS CONTROL
FA C T S  A B O U T  I N H
Your doctor has prescribed
isoniazid, or INH, to protect you
from getting tuberculosis (TB).
Here are some things you should
know about INH:
• To prevent TB, you must take
ALL of your medicine for the
WHOLE time. This means
–6 months if you are an adult
–9 months if you are younger
than 18
–12 months if you are HIV
positive
–12 months if you have
scarring on your chest x-ray
• Try to take INH at the same
time every day. Many people
find it best to take INH just
before bedtime because it
makes them a little sleepy.
• If you forget to take your
medicine, do not take extra
pills the next day, but tell your
doctor or nurse. Never take
more than the prescribed
amount each day.
• Do NOT drink alcohol while
you are taking INH.
• Do not take other medicines,
including Tylenol, unless you
ask your doctor first.
• INH is the best medicine to
fight TB germs, and it is safe.
But as with any medicine, a few
people may have side effects.
The possible side effects are
–Nausea
–Vomiting
–Loss of appetite
–Yellow skin and eyes
–Dark urine 
–Skin rash
If you have any of these side
effects, stop taking INH and
tell your doctor or nurse right
away.
• While you are taking INH, you
need to see your doctor or
nurse every month to
–Make sure you’re not having
any side effects
–Check your health and
answer your questions
–Get the next month’s supply
of INH
• It’s not easy to take medicine
when you don’t feel sick. But by
taking INH now, you reduce
your risk of getting TB disease
in the future. Treatment for TB
disease is more difficult.
Rudolph W. Giuliani, Mayor
Neal L. Cohen, Commissioner
If you have any questions, call your clinic.
APPENDIX F: Tuberculin Screening—Initial Form
Chart #:_______________________  Social Security Number (optional)  ______-______-______
Name:  Last: _________________________  First: ________________________ Middle: ______
Address: __________________________________________________________________________
City: ______________________________  State:____________________________   Zip: ________
Home Telephone:  (      ) ______ – _____________   Work Telephone:  (      ) ______ – ______
Beeper: ______________________________  Hospital mailing address: ____________________
Birthdate: _____ / _____ / _____ Sex:   ❑ Male   ❑ Female
Race/Ethnicity:          ❑ White, not Hispanic ❑ Asian or Pacific Islander
❑ Black, not Hispanic ❑ American Indian or Alaskan Native
❑ Hispanic ❑ Other specify: ____________________
Were you born in the U.S.? ❑ Yes ❑ No
If No, country of birth: ____________________________
Year entered the U.S.:  ______   or    ❑ Don’t know
Have you ever received BCG (Bacille Calmette-Guérin) vaccine? 
(BCG is a tuberculin vaccine, NOT a PPD or  tuberculin skin test).
❑ Yes ❑ No ❑ Don’t know
If yes, year received last vaccine:  ______  or ❑ Don’t know year.
Have you ever had active TB?    ❑ Yes ❑ No ❑ Don’t know
Current TST Result Date: ___/ ___/ ___ Current TST Result: ____ mm
Previous TST Result Date: ___/___/___ Result (circle one): Positive / Negative
Documented?❑  Yes ❑  No
Which of the following describes your work location/ward?  (Check only one.)
❑  1.Work 75% or more of the time at one location/ward,
specify:___________________________________________
❑  2.Work at multiple locations/wards 
What is your job title/occupation? __________________________________________________
Department: ____________________________
Date Started at Harlem Hospital  (month/year)  ___ /___
Physicians and Physician’s Assistants, please specify service/specialty: ____________________
Date form completed:  ___/___/___ ___________________________________________
Signature
APPENDIX G: Fast Track Employee Self-Assessment Form
Charles P. Felton
National Tuberculosis Center
at Harlem Hospital
2238 Fifth Ave., First Floor
New York, N.Y. 10037
Date: ____/ ____/ ____  
Current Medication: Date medication started: ___/ ___/ ___
Do you have any of these complaints?
Yes No Yes No Yes No
Fever ❑ ❑ Poor appetite ❑ ❑ Itching ❑ ❑
Rash ❑ ❑ Nausea ❑ ❑ Fatigue ❑ ❑
Vomiting ❑ ❑ Problem with Pain, tingling or
Vision ❑ ❑ numbness in
legs or arms ❑ ❑
Abdominal Pain ❑ ❑ Yellow Eyes ❑ ❑ Dark Urine ❑ ❑
Other (specify):
Do you need to see doctor? Yes ❑ No ❑
Did you miss any medication? Yes ❑ No ❑ If yes, how many days? ______________
Do you need to see Educator? Yes ❑ No ❑
Triage decision: ❑ MD F/Up             ❑ Refill Medications
_________________________________________ Date:  ______/ ______/ _____
Coordinator’s Signature
Return visit date:   ______/ ______/ _____
APPENDIX H: Fast Track Activity Form 
Name: _______________________________________Chart #: ________________________________
DATE ACTIVITIES
APPENDIX I: Fast Track Visit Outcome Form 
Name: _______________________________________Chart #: ________________________________
VISIT DATE OUTCOMES
APPENDIX J (PART 1): Questionnaire on TB Knowledge
This questionnaire is designed to find out how much you know about tuberculosis.
PLEASE INDICATE IF THE FOLLOWING STATEMENTS ARE TRUE OR FALSE, OR IF YOU DON’T KNOW.
True False Don’t Know
1. It is easier to get TB by living in crowded conditions. 1 0 9
2. A person can get TB by sharing dishes or utensils with 
someone  who has TB. 1 0 9
3. A person can get TB by touching something that someone
with TB has coughed on. 1 0 9
4. You are more likely to get TB from a stranger than from a
family member. 1 0 9
5. Which of the following are symptoms of TB?
a.  losing weight 1 0 9
b.  having night sweats 1 0 9
c.  coughing 1 0 9
d.  swelling of feet 1 0 9
e.  yellow sputum 1 0 9
6. A positive TB skin test means that you already have TB disease. 1 0 9
7. Taking medication can cure almost all cases of TB. 1 0 9
8. Treatment of TB can be completed in as little as one month. 1 0 9
9. People who have HIV are more likely to get sick with TB. 1 0 9
10. Being infected with TB does not mean you are sick with TB. 1 0 9
11. A person with TB disease can look and feel fine. 1 0 9
ANSWER KEY: 
1)  T;  2)  F;  3)  F;  4)  F; 5)  a=T, b=T, c=T, d=F, e=F;  6)  F;  7)  T;  8)  F; 9)  T; 10)  T; 11)  T.
APPENDIX J (PART 2): Questionnaire on Attitudes about 
Treatment for TB Infection and Disease
Scale 1 Strongly Disagree
2 Disagree Somewhat
3 Agree Somewhat
4 Strongly Agree
PLEASE CIRCLE
1. I believe I have the TB germ in your body. 1  2  3  4
2. My positive TB test is likely to be because of the BCG vaccine. 1  2  3  4
3. The BCG vaccine will prevent me from getting TB disease. 1  2  3  4
4. No matter what I do, I could still get TB disease. 1  2  3  4
5. People with positive skin tests may need to take TB medicine. 1  2  3  4
6. Taking medicine to prevent my getting TB disease is very important. 1  2  3  4
7. Taking my medicine is a hassle.                                              1  2  3  4
8. It will take something very serious to keep me from taking my medicine. 1
2  3  4
9. Going to appointments is more trouble than it is worth.                  1
2  3  4
10. If I do the right thing, I can avoid getting sick with TB disease.        1
2  3  4
Some people don’t complete their treatment for TB infection. Please give three reasons
why someone would not complete their treatment.
1) _________________________________________________________________________________
2) _________________________________________________________________________________
3) _________________________________________________________________________________
APPENDIX K: Sources for TB Educational Materials
 LOCAL OR STATE HEALTH DEPARTMENT OR AMERICAN LUNG
ASSOCIATION
 THE NEW YORK CITY DEPARTMENT OF HEALTH 
Tuberculosis Control Program
Education and Training Unit
253 Broadway, 22nd floor, Box 72-A
New York, NY 10007
Phone: (212) 442-9968   Fax: (212) 442-9998
Website: www.ci.nyc.ny.us/health
 FRANCIS J. CURRY NATIONAL TB CENTER
3180 Eighteenth Street, Suite 101
San Francisco, CA 94110
Phone: (415) 502-4600 / Fax: (415) 502-4620
Website: www.nationaltbcenter.edu
 CHARLES P. FELTON NATIONAL TB CENTER AT HARLEM HOSPITAL
2238 Fifth Avenue, First Floor
New York, NY 10037
Phone: (212) 939-8254 / Fax: (212) 939-8259
Website: www.harlemtbcenter.org
 NEW JERSEY MEDICAL SCHOOL NATIONAL TB CENTER
65 Bergen Street, Suite GB-1
Newark, NJ 07107-3001
Phone: (973) 972-3270 / Fax: (973) 972-3268
Website: www.umdnj.edu/ntbc
 CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)
Division of Tuberculosis Elimination
Communications and Education Branch
1600 Clifton Road, N.E., Atlanta, GA 30333
Phone: (405) 639-8135 / Fax: (404) 639-8960
Website: www.cdc.gov/nchstp/dtbe.html
 LIVE INTERACTIVE SATELLITE TELECONFERENCES
State health departments, the Francis J. Curry National Tuberculosis Center, and the
CDC periodically sponsor nation-wide or regional satellite teleconferences on
relevant TB topics. Up to date comprehensive information about future broadcasts
is available from the Public Health Training Network web site at
http://www.cdc.gov/phtn.
APPENDIX L: Fast Track Evaluation Form 
THE CHARLES P. FELTON NATIONAL TUBERCULOSIS CENTER AT HARLEM HOSPITAL
Name:____________________________________________________________________________
Date: ____________________________________________________________________________
We would like to thank you for participating in the Fast Track program.  We appreciate
your assistance in answering the following questions.
1. Did you miss any of your scheduled clinic visits?
❑ Yes     ❑ No _____    If no, go ❑ to question #3
2. If yes, why did you miss your appointments?
________________________________________________________________________________
❑ Did not remember
❑ Did not have the time 
❑ Still had medication left 
❑ Could not get time-off work 
❑ Other (specify)
3. Did you miss any doses/days of medication? ❑ Yes ❑ No
If no go to question #6
4. If yes, in a typical week, how many days did you miss? Number of days missed _________
5. In a typical month, how many weeks did you miss? Number of weeks missed __________
6. How many months of treatment did you take? Number of months____________________
7. Did you have any side effects taking your medication? ❑ Yes ❑ No
Specify ___________________________________________________________________________
8. Did you have any difficulties taking your medication? ❑ Yes ❑ No
Specify ___________________________________________________________________________
9. Was the Fast Track program helpful in getting you to 
complete therapy? ❑ Yes ❑ No
If no, why not? ___________________________________________________________________
10. What did you find the most helpful?
❑  Educational materials 
❑  Short wait time
❑  Program well organized 
❑  Reminders 
❑  Being able to make appointments at a convenient time and place
❑  Prompt availability of medication 
❑  Other (specify) ________________________________________________________
11. What are other factors that helped you?
❑  Self motivation  
❑  Family support 
❑  Afraid of TB
❑  Concern for family/friends
❑  Other (specify) ________________________________________________________
12. What else could be done to make it easier for others to start and complete treatment for
latent tuberculosis infection? ________________________________________________________
CHARLES P. FELTON 
NATIONAL TUBERCULOSIS CENTER AT HARLEM HOSPITAL
2238 Fifth Avenue, First Floor
New York, NY 10037
Phone 212-939-8254   Fax 212-939-8259
Website www.harlemtbcenter.org
